Cassava Sciences One Step Closer to Alzheimer’s Disease Treatment

  Cassava Sciences, Inc. (Nasdaq: SAVA) has announced a positive interim safety review of its lead candidate, simufilam currently under evaluation in patients with Alzheimer’s disease. An independent Data and Safety Monitoring Board recommended that Cassava’s Phase 3 studies continue as planned, without modification. Chairman of the Board, President & CEO of Cassava, Remi Barbier,…